Apr 9 |
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
|
Apr 3 |
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
|
Mar 27 |
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
|
Mar 27 |
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
|
Mar 18 |
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
|
Mar 14 |
Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
Mar 12 |
Aligos Therapeutics GAAP EPS of -$0.22 beats by $0.05, revenue of $2.68M beats by $1.08M
|
Mar 12 |
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
|
Mar 5 |
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
|
Feb 26 |
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
|